The central claim of the work is striking in its simplicity. As organisms age, the fatty acyl chains attached to their membrane lipids tend to become longer. This is not a random drift but a systematic shift, detectable in multiple tissues and conserved between evolutionarily distant species. That kind of cross-species conservation is exactly what biogerontologists look for when they argue that a process is a genuine driver of aging rather than a mere byproduct of it. The field has formalized such criteria before, and lipid changes have long hovered near the top of candidate lists without quite earning hallmark status.

What elevates this study above earlier correlational work is the causal test. Li and colleagues did not simply document that lipid chains lengthen with age; they genetically shortened them. In the roundworm Caenorhabditis elegans, a workhorse of aging research, manipulating the enzymes that elongate fatty acid chains produced animals with shorter lipid chains and, crucially, longer lifespans. That experiment establishes chain length as a causal contributor to aging, not just a molecular passenger. In the strict logic of the hallmark framework, causation is the hardest bar to clear, and this result clears it.

To understand why chain length matters, it helps to revisit the basic physics of membranes. Every animal cell is wrapped in a lipid bilayer, a two-molecule-thick sheet in which fatty acyl chains pack side by side to form a fluid yet barrier-forming matrix. The physical properties of that sheet depend intimately on the chains themselves. Longer saturated chains pack together more tightly and melt at higher temperatures, making membranes thicker, stiffer and less permeable. Shorter chains, and chains interrupted by double bonds, introduce kinks and gaps that keep the bilayer fluid. Membrane fluidity, in turn, governs the behavior of every protein embedded in the lipid sea, from receptors and ion channels to the transporters that shuttle nutrients across the cell boundary.

A long line of research has connected membrane composition to lifespan. The membrane pacemaker hypothesis, developed from comparative physiology, notes that long-lived species tend to have membranes enriched in more highly unsaturated, shorter-chain fatty acids, which are less prone to peroxidative damage. Polyunsaturated fatty acids with many double bonds are vulnerable to attack by reactive oxygen species, and peroxidized lipids propagate damage to neighboring molecules, corrupting membrane integrity and generating toxic aldehyde byproducts. A membrane built from longer, more saturated chains may therefore be a membrane that oxidizes more readily as cellular defenses weaken with age, creating a slow-burning source of the molecular damage that characterizes aging tissue.

The elongation chemistry itself is carried out by a family of enzymes known as ELOVL proteins, the elongation of very long chain fatty acids family, which add two-carbon units to growing acyl chains in the endoplasmic reticulum. Mammals encode seven ELOVL isoforms with distinct tissue distributions and substrate preferences, and their activity is tuned by diet, hormonal state and nutrient-sensing pathways. Several of the pathways most famous for extending lifespan in model organisms, including reduced insulin and insulin-like signaling and dietary restriction, are known to remodel lipid metabolism, and earlier studies in worms linked specific elongase and desaturase enzymes to longevity. The new work places those scattered observations into a coherent framework: lipid chain elongation is not an incidental metabolic side effect but a recurring feature of the aging process itself.

The cross-tissue and cross-species breadth of the finding is what makes it genuinely viral material for the aging field. Many proposed hallmarks of aging are tissue-specific or species-specific, which complicates efforts to translate findings from worms and mice to humans. A lipid signature that recurs across tissues and organisms suggests a deep, conserved mechanism, plausibly rooted in the universal physics of membranes and the shared biochemistry of fatty acid synthesis. It also suggests that lipidomics, the systematic measurement of the lipidome, could serve as a biomarker platform for biological age, complementing epigenetic clocks and proteomic signatures that currently dominate the aging-biomarker conversation.

Perhaps the most provocative element of the story is the claim of reversibility. If lipid chain length shifts with age and can be pushed back toward a younger profile, either genetically or pharmacologically, then membrane composition joins the short list of aging features that are demonstrably plastic. The worm experiment shows that shortening chains extends lifespan, which is proof of principle in a simple organism. Whether the same intervention works in mammals is now the obvious next question, and it is a difficult one, because lipid metabolism in mammals is entangled with energy storage, signaling and inflammation in ways that a microscopic worm’s is not. Elongases are not interchangeable; inhibiting them globally could disrupt the synthesis of essential signaling lipids and the very-long-chain fatty acids required for brain and skin function.

There are also important caveats to keep in view. The highlighted study is published alongside a subscription-gated commentary, and the full experimental details, including which tissues and species were profiled and how the lifespan experiments were controlled, will determine how broadly the conclusion generalizes. Correlations between lipid composition and aging have been reported before, and some lipid changes with age reflect shifts in diet, microbiome and body composition rather than cell-autonomous programs. Disentangling those threads will require careful work. Nonetheless, the causal worm result gives the field something it rarely gets: a single, well-defined molecular parameter, acyl-chain length, that can be tuned and its consequences measured directly.

For now, the takeaway is conceptual rather than clinical. Aging biology has been converging on the idea that aging is not one process but a bundle of interacting processes, and that the most useful hallmarks are those that are conserved, causal and amenable to intervention. Lipid acyl-chain elongation now satisfies all three criteria, at least in one organism, and the demonstration that shortening lipid chains lengthens life will send many laboratories back to their lipidomics data with fresh eyes. If the finding holds up in mammals, the humble fatty acid chain, long treated as a passive structural element of the cell, may turn out to be one of the levers by which the pace of aging is actually set.

Subject of Research: Lipid acyl-chain elongation as a conserved and causal hallmark of biological aging

Article Title: Lipid elongation as a hallmark of aging

Article References: Pang, S. (2026). Lipid elongation as a hallmark of aging. Nature Aging. https://doi.org/10.1038/s43587-026-01229-5

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01229-5

Keywords: aging, lipidomics, fatty acid elongation, membrane fluidity, ELOVL enzymes, Caenorhabditis elegans, lifespan extension, hallmarks of aging, membrane composition, biogerontology, lipid peroxidation, Nature Aging

The team, led by ophthalmology researchers at the Eye Institute of Fudan University in Shanghai, quantified systemic aging using three complementary instruments. The first was PhenoAge acceleration, a measure derived from clinical biomarkers that estimates how much faster a person’s physiology is aging compared with their chronological peers. The second was age acceleration calculated by the Klemera-Doubal method, another biomarker-based biological age algorithm with a long track record in aging research. The third was a frailty index, a cumulative score built from deficits across health domains that captures the loss of physiological reserve characteristic of advanced aging. Each of these measures tells a slightly different story about aging, and the researchers wanted to know whether all of them converged on the same retinal signature.

That signature turned out to be strikingly consistent. Across all three aging metrics, higher biological age acceleration and greater frailty were associated with reduced macular thickness, with the effect spanning every inner retinal subfield measured by optical coherence tomography. The standardized effect sizes ranged from −1.386 to −0.421, and all associations remained highly significant after correction for multiple comparisons, with false discovery rate adjusted P values below 0.001. In practical terms, people whose bodies were aging faster than their birthdays implied tended to have measurably thinner retinas, and the relationship held whether aging was defined by molecular biomarkers, composite algorithms, or the clinical syndrome of frailty.

Optical coherence tomography, the imaging technology behind these measurements, deserves a moment of explanation. Originally described in Science in 1991, OCT uses low-coherence interferometry to generate cross-sectional images of biological tissue with micrometer-scale resolution. In the UK Biobank, tens of thousands of participants underwent retinal OCT scanning, producing an enormous, standardized dataset of retinal layer thicknesses. Because the retina is embryologically part of the central nervous system and shares vascular and metabolic characteristics with the brain, changes in its structure have been proposed as noninvasive biomarkers for neurological and systemic disease. Previous work has linked retinal thinning to cardiovascular risk, Alzheimer disease, and early age-related macular degeneration, but the broader question of how whole-body aging states map onto retinal structure had remained poorly characterized.

The most technically ambitious part of the new study involved the plasma metabolome. Blood samples collected from participants between 2006 and 2010 had been profiled using nuclear magnetic resonance spectroscopy, a platform that quantifies hundreds of circulating metabolites, including lipoprotein subclasses, fatty acids, amino acids, and glycolysis-related markers. From this high-dimensional data, the researchers derived metabolic signatures of aging using elastic net regression, a machine learning technique that selects sparse, predictive combinations of variables while guarding against overfitting. The resulting metabolomic aging signatures were then tested as statistical mediators of the relationship between biological aging and retinal thinning.

The mediation results were the study’s headline finding. Metabolic signatures accounted for 81.14 percent of the association between PhenoAge acceleration and macular thickness, 19.92 percent of the association for Klemera-Doubal method age acceleration, and 32.27 percent of the association for the frailty index, with all mediation effects significant after FDR correction. These proportions are remarkable, particularly for PhenoAge, and they suggest that circulating metabolites are not merely passive bystanders in the aging process but plausible conduits through which systemic senescence reaches the neurosensory retina. The retina is among the most metabolically demanding tissues in the body, with photoreceptors and the retinal pigment epithelium locked in a tightly coupled metabolic ecosystem that depends on glucose, lactate shuttling, and mitochondrial oxidative metabolism. Disruption of systemic metabolic homeostasis, the authors argue, is therefore well positioned to leave structural fingerprints in retinal tissue.

The study also incorporated the exposome, the concept introduced by cancer epidemiologist Christopher Wild in 2012 to describe the totality of environmental exposures an individual experiences across a lifetime. The researchers assembled exposome factors from phenotypic data covering lifestyle, diet, air pollution, and mental health. Their integrative analyses showed that adverse exposome profiles, including tobacco exposure, poor diet, air pollution, and negative psychosocial states such as loneliness and depression, were each correlated with reduced macular thickness. More importantly, systemic aging and metabolic dysregulation emerged as significant statistical intermediaries within these multidimensional pathways, meaning that environmental burdens appear to translate into retinal change at least partly by accelerating biological aging and reshaping the circulating metabolome.

This framing has implications that extend well beyond ophthalmology. If the retina reflects the convergence of environmental stress, metabolic dysregulation, and biological aging, then a routine retinal scan could in principle serve as a rapid, noninvasive readout of an individual’s cumulative aging trajectory. The findings align with a growing body of work on retinal oculomics, including phenome-wide analyses of UK Biobank OCT images that have linked ocular measurements to systemic health, and epidemiological studies showing that ambient air pollution is associated with retinal thinning and age-related macular degeneration. The new study unifies these threads by proposing an explicit causal architecture in which exposures act on aging biology, aging biology acts on metabolism, and metabolism acts on the retina.

The authors are careful about what their statistics can and cannot show. Mediation analysis in observational data identifies statistical intermediaries, not proven causal mechanisms, and the cross-sectional design of the UK Biobank baseline assessments means that temporal ordering cannot be fully established. The metabolomic platform used, while comprehensive for lipids and small molecules, does not capture every biologically relevant compound, and the elastic net signatures are predictive composites rather than single causal metabolites. Residual confounding by socioeconomic factors, which shape both exposome and health outcomes, remains a persistent challenge in cohort studies of this kind. Nevertheless, the sheer scale of the cohort, the consistency of the associations across three independent aging metrics, and the rigorous multiple-comparison correction lend considerable weight to the central conclusion.

For the aging research community, the study adds the retina to the growing list of organs whose structural integrity tracks systemic biological age, and it elevates plasma metabolism to the status of a key correlate of neurosensory retinal health. For clinicians, it hints at a future in which retinal imaging, already fast and inexpensive, might help identify people whose bodies are aging faster than their years, potentially guiding earlier interventions on smoking, diet, air quality, and psychosocial wellbeing. And for the public, the message is a vivid one: the same exposures that wear down the heart, the brain, and the metabolism may also be quietly etched into the tissue that lets you read this page. The eye, it seems, does not only take in the world; it keeps a record of what the world has done to us.

Subject of Research: Associations between systemic biological aging, frailty, exposome factors, plasma metabolomics, and retinal structural changes in the UK Biobank

Article Title: Association of systemic aging and frailty with retinal alterations: insights from an integrated exposome and metabolome framework

Article References: Chen, T., Wang, D., Ma, Y., Ye, Y., Wang, X., Lei, Y., Zhou, X., & Zhao, J. (2026). Association of systemic aging and frailty with retinal alterations: insights from an integrated exposome and metabolome framework. GeroScience. https://doi.org/10.1007/s11357-026-02572-6

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02572-6

Keywords: retinal oculomics, biological aging, frailty, plasma metabolomics, exposome, UK Biobank, macular thickness, optical coherence tomography, PhenoAge, mediation analysis, GeroScience, aging biomarkers

The research, led by Takashi Shida of the Tokyo Metropolitan Institute for Geriatrics and Gerontology and colleagues, drew on participants from the Itabashi Longitudinal Study on Aging, an ongoing community-based cohort in a residential ward of northern Tokyo. The team analyzed data from 529 adults aged 65 and older who took part in the 2025 survey wave, a group in which 54.3 percent were women. Frailty, the state of heightened vulnerability that leaves older adults at risk of falls, disability, hospitalization, and death, was assessed using the revised Japanese version of the Cardiovascular Health Study criteria, a validated instrument that scores weight loss, exhaustion, low physical activity, weakness, and slowness. Of the 529 participants, 32, or 6.0 percent, met the criteria for frailty.

The central measurement was the concentration of NAD+ in whole blood, quantified in micromoles per liter. Whole-blood NAD+ is a composite signal: it reflects the molecule’s presence inside red blood cells, white blood cells, and platelets, as well as whatever circulates in plasma. Because red blood cells lack mitochondria and rely heavily on NAD+ for glycolysis and antioxidant defense, the blood compartment offers a convenient, if imperfect, window into systemic NAD+ metabolism. The researchers found that the median whole-blood NAD+ concentration was measurably lower among participants with frailty than among those without it, at 24.00 versus 25.00 micromoles per liter, a difference that reached statistical significance with a P value of 0.007.

To move beyond a simple group comparison, the team built multivariable regression models that adjusted for the most obvious confounders: age, sex, and fasting time before the blood draw, the last of which matters because NAD+ levels can fluctuate with recent food intake. After these adjustments, each 1 micromole per liter increase in whole-blood NAD+ concentration was associated with 13 percent lower odds of frailty, with an odds ratio of 0.871 and a 95 percent confidence interval spanning 0.780 to 0.970, and a P value of 0.013. In a cohort where the median sits near 25 micromoles per liter, a one-unit shift is a meaningful fraction of the biological range, which makes the effect size noteworthy rather than trivial.

The investigators then subjected their finding to a battery of robustness checks that reveal how carefully the result was constructed. Restricted cubic spline analysis, a technique that allows the relationship between NAD+ and frailty to bend and curve freely rather than assuming a straight line, showed no clear evidence of nonlinearity, suggesting the association behaves approximately linearly across the observed range. Because frailty was relatively rare in the sample, the team also ran a Firth penalized-likelihood logistic regression, a method designed to produce more stable estimates when outcomes are infrequent and conventional models risk bias. Under this broader covariate adjustment, the association held firm, with an odds ratio of 0.880 and a confidence interval of 0.782 to 0.986.

But the story took a more complicated turn when the researchers added hematocrit, the proportion of blood volume occupied by red blood cells, to the model. With that adjustment, the association weakened and lost statistical significance, with the odds ratio drifting to 0.911 and the confidence interval crossing unity at 0.800 to 1.034. This attenuation is not a failure of the study; it is one of its most informative results. It suggests that part of the apparent link between blood NAD+ and frailty may be explained by blood cell composition itself. Frail older adults often have altered hematological profiles, including tendencies toward anemia and shifts in red cell indices, and since the vast majority of whole-blood NAD+ resides within blood cells, differences in cell counts and packing could masquerade as, or at least substantially contribute to, differences in NAD+ concentration.

This caveat places the new findings within a lively and sometimes contentious scientific debate. NAD+ has become one of the most hyped molecules in the longevity world, with supplements such as nicotinamide riboside and nicotinamide mononucleotide marketed aggressively on the premise that restoring youthful NAD+ levels can slow aging. Human evidence, however, has been mixed. Some studies have reported that whole-blood NAD+ contents decline with age, while others, including a recent analysis published in Nature Metabolism, found that human whole-blood NAD+ levels do not vary with age or with lifestyle interventions. Blood NAD+ has also been reported to be reduced in very old patients hospitalized for heart failure, hinting that the molecule may track with disease severity rather than chronological age per se. The Itabashi study adds a crucial piece: a community-dwelling, non-hospitalized population in which the association with frailty, a clinical syndrome rather than a single disease, was detectable.

The study’s design imposes important limits on interpretation. As a cross-sectional analysis, it captures a single moment in time and cannot determine whether low NAD+ contributes to causing frailty, whether frailty and its metabolic consequences deplete NAD+, or whether both are driven by a shared underlying process such as chronic inflammation, mitochondrial dysfunction, or poor nutrition. The frailty group was also small, with only 32 affected participants, which limits statistical power and explains the team’s recourse to penalized regression. And the whole-blood measurement, while practical and increasingly standardized, cannot distinguish between NAD+ dynamics in muscle, brain, immune cells, and other tissues where the molecule’s age-related decline is thought to matter most. The authors themselves emphasize that further studies using cell- and tissue-specific measurements are needed to clarify the relationship between NAD+ metabolism and frailty.

Those caveats notwithstanding, the significance of the work lies in its grounding. Much of the NAD+ literature rests on cell culture experiments, animal models, or small and highly selected human samples. Here, the association emerges from ordinary older adults living at home in a Tokyo ward, measured with a validated frailty instrument and adjusted for the mundane but essential variables of age, sex, and fasting status. If blood NAD+ does prove to be a genuine marker of physiological resilience, even one partly confounded by blood cell composition, it could eventually help clinicians identify which older patients are silently sliding toward frailty before falls and disability make it obvious. Biomarkers of frailty are a recognized public health priority, and most current candidates, from inflammatory cytokines to metabolomic signatures, remain far from clinical deployment.

The road ahead will require longitudinal follow-up within cohorts like Itabashi, where repeated NAD+ measurements can be tested as predictors of incident frailty, and intervention studies in which NAD+-boosting compounds are evaluated against hard clinical endpoints rather than blood chemistry alone. Recent work comparing different NAD+ precursors has shown that they exert differential effects on circulating NAD and microbial metabolism in humans, underscoring how much remains unknown about how these interventions behave in the body. Exercise training, for its part, has been shown to reverse the age-dependent decline in NAD+ salvage capacity in human skeletal muscle, pointing to lifestyle approaches that may act on the same pathway without a pill. For now, the Itabashi findings should be read as a carefully qualified signal rather than a prescription: a molecule central to energy metabolism and cellular signaling appears to run low in the blood of frail older adults, and untangling whether that deficit is a driver, a passenger, or a mirror of declining resilience is now one of the most compelling questions in the biology of aging.

Subject of Research: Association between whole-blood NAD+ concentration and frailty in community-dwelling older adults

Article Title: Association between whole-blood NAD+ concentration and frailty in community-dwelling older adults: the Itabashi Longitudinal Study on Aging

Article References: Shida, T., Hatanaka, S., Kojima, N., Osuka, Y., & Sasai, H. (2026). Association between whole-blood NAD+ concentration and frailty in community-dwelling older adults: the Itabashi Longitudinal Study on Aging. GeroScience. https://doi.org/10.1007/s11357-026-02545-9

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02545-9

Keywords: NAD+, frailty, aging, older adults, whole blood, biomarkers, energy metabolism, sirtuins, hematocrit, GeroScience, Itabashi Longitudinal Study, geriatrics

The study, led by Raphaël Waziry of Columbia University Irving Medical Center together with colleagues including Sara Hägg of the Karolinska Institutet, tackled a question that has long hovered over the booming field of geroscience: do the different biomarkers of aging, measured in different tissues, actually tell the same story about the same person? Aging researchers currently rely on a patchwork of measures. Telomere length tracks the protective caps on chromosomes, which erode with each cell division. Epigenetic clocks read chemical tags called methyl groups scattered across the genome, whose patterns shift predictably as we age. Physiology-based measures combine routine blood chemistry values, such as albumin, creatinine, glucose, and C-reactive protein, into a composite estimate of biological age. Whether these domains of aging biology converge within a single individual, and whether a measurement in one tissue reflects measurements in another, had remained largely unresolved.

To answer it, the team turned to the Health and Retirement Study, a nationally representative longitudinal survey of more than 37,000 Americans aged 50 and older, coordinated by the University of Michigan’s Institute for Social Research. Participants who provided saliva samples during the 2008 interview wave had their average telomere length measured using quantitative PCR, a technique that compares the copy number of telomere sequences to a single-copy gene to produce a ratio proportional to mean telomere length. Eight years later, in 2016, many of the same participants contributed venous blood samples, which were processed within 24 to 48 hours and analyzed at a CLIA-certified laboratory at the University of Minnesota. In total, 2,406 individuals had complete data on both salivary telomere length and blood-based physiology measures, and 1,029 also had DNA methylation data, allowing direct within-person comparisons across tissues.

The DNA methylation analysis was unusually thorough. Rather than relying on a single epigenetic clock, the researchers computed eight of them, spanning the field’s history from first-generation chronological age predictors to second-generation mortality-focused algorithms. These included the original Horvath pan-tissue clock built on 353 CpG sites across 51 healthy tissues and cell types; the Hannum clock, comprising 71 CpG sites developed in whole blood; PhenoAge, based on 513 CpG sites and trained on phenotypic age; GrimAge, which incorporates epigenetic surrogates for a dozen plasma proteins along with smoking pack-years and is considered among the strongest predictors of time to death, coronary heart disease, and cancer; the skin and blood clock built on 391 CpGs; and the more compact Lin, Weidner, and VidalBralo clocks, which use 99, three, and eight CpG sites respectively. On the physiology side, the team used phenotypic age, an algorithm derived from Gompertz proportional hazard models that integrates nine blood biomarkers: albumin, creatinine, glucose, log C-reactive protein, lymphocyte percent, mean cell volume, red blood cell distribution width, alkaline phosphatase, and white blood cell count.

The headline result was strikingly consistent. Across every blood-based measure examined, longer salivary telomeres were associated with slower biological aging, an inverse relationship that held after adjusting for sex, the interaction between sex and telomere length, and the eight-year gap between the saliva and blood collections. When participants were grouped into tertiles of telomere length, those in the highest tertile showed biological ages roughly one to four years younger than those in the lowest tertile, depending on the clock. The largest effects appeared for the compact Weidner clock, with a beta coefficient of minus 3.97 years, followed by Lin at minus 3.45 years and GrimAge at minus 3.33 years, the latter highly statistically significant. The pattern persisted even in sensitivity analyses that excluded telomere measurements with a T/S ratio above 2.0, values more likely to be artifacts in salivary samples, and when the sex interaction term was dropped from the models.

Notably, the cross-tissue correlations, while statistically significant, were modest in magnitude, with coefficients such as minus 0.067 for the Lin clock and minus 0.064 for Weidner. This stands in sharp contrast to the intra-tissue comparisons within blood, where DNA methylation clocks correlated strongly with the physiology-based phenotypic age. GrimAge led the pack with a correlation coefficient of 0.75, followed by Hannum at 0.68 and the skin and blood clock at 0.66, all highly significant. The interpretation is nuanced: within a single tissue, the different domains of aging biology move together robustly, but the signal weakens when it must travel across tissues, time, and measurement technologies. An eight-year interval between samples, which the authors adjusted for but could not eliminate, likely contributes to this attenuation, as does the well-documented fact that saliva and blood differ substantially in the concentration and abundance of their molecular analytes.

One of the most intriguing findings emerged from the finer-grained analysis of individual physiology biomarkers. When each of the nine blood analytes was correlated separately with the DNA methylation clocks, the strength of association varied widely. Creatinine, a marker of kidney function, and lymphocyte percent, a marker of immune status, showed the strongest correlations with epigenetic aging measures, in some cases exceeding their correlations with chronological age itself. Alkaline phosphatase, by contrast, showed little relationship with any of the clocks. The authors suggest this points to potentially prominent roles for renal function and immunity in accelerating or decelerating biological aging at the epigenetic level, a hypothesis that aligns with longstanding observations that immune cell composition shifts and kidney decline are hallmarks of the aging process.

The study also revealed sex-based variation. In models stratified by sex, the effect estimates linking each tertile increase in telomere length to blood-based aging measures differed between males and females across the various clocks. This was anticipated by the researchers, who included a sex-by-telomere interaction term in their primary models based on prior evidence that telomere dynamics differ between the sexes, with women generally maintaining longer telomeres than men of the same chronological age. The precise biological underpinnings of these differences, whether hormonal, inflammatory, or related to differential exposures across the life course, remain an open question for future work.

The practical implications could prove significant. Saliva is among the most accessible human tissues: collection requires no needles, no trained phlebotomist, and minimal equipment, and samples are cheaper and easier to ship and store than blood. It has already proven its worth in therapeutic drug monitoring for conditions such as epilepsy, diabetes, and multiple sclerosis, and in clinically difficult populations where venous access is not feasible. The new findings suggest that a salivary telomere measurement, even taken years before a blood draw, carries real information about a person’s epigenetic and physiological aging status. For vulnerable populations, including frail elderly patients, young children, and people in low-resource settings, this opens the possibility of integrating aging biology monitoring into routine care using whichever tissue is accessible. The authors caution, however, that saliva composition is influenced by circadian rhythms, medications, sympathetic and parasympathetic nervous activity, and conditions ranging from diabetes to infectious disease, and that immune cell contamination can confound salivary DNA methylation measurements.

The researchers are candid about the limitations. The biomarkers were measured at two different time points, introducing potential imprecision despite statistical adjustment. Only telomere length was available in saliva, so no epigenetic clocks could be computed from that tissue. Each individual was measured only twice, precluding analysis of within-person trajectories over long periods. And because participants were aged roughly 59 to 72 at saliva collection, the results cannot be extrapolated to younger adults. Still, the study’s scale, national representativeness, and unusually comprehensive battery of aging measures make it one of the clearest demonstrations to date that the body’s aging clocks are connected across tissues. As epigenetic testing becomes cheaper and repeated measurement becomes more feasible, the convergence of telomere, methylation, and physiology-based measures, whether sampled from blood or saliva, may form the foundation for the surrogate endpoints that geroscience trials have long sought, and for a future in which a routine swab of the cheek helps clinicians track how quickly, or slowly, their patients are growing old.

Subject of Research: Cross-tissue correspondence between salivary telomere length and blood-based DNA methylation and physiology biomarkers of biological aging in older adults

Article Title: Connections between cross-tissue and intra-tissue biomarkers of aging biology in older adults

Article References: Waziry, R., Gu, Y., Williams, O., & Hägg, S. (2023). Connections between cross-tissue and intra-tissue biomarkers of aging biology in older adults. Epigenetics Communications, 3(1), Article 7. https://doi.org/10.1186/s43682-023-00022-4

Image Credits: AI Generated

DOI: 10.1186/s43682-023-00022-4

Keywords: biological aging, telomeres, DNA methylation, epigenetic clocks, saliva biomarkers, blood biomarkers, GrimAge, phenotypic age, Health and Retirement Study, geroscience, biomarkers, older adults

The study, led by Thomas Jonkman, Erik van Zwet, and Bastiaan Heijmans of Leiden University Medical Center together with Anne Richmond and Riccardo Marioni of the University of Edinburgh, drew on DNA methylation data from 4,058 whole blood samples collected across six Dutch biobanks in the BIOS Consortium. Participants ranged from 18 to 87 years old. Using the EpiDISH deconvolution algorithm, the team estimated the proportions of twelve distinct blood cell types in each sample, including neutrophils, monocytes, natural killer cells, and naive and memory subsets of B cells and T cells. Neutrophils dominated the average blood profile, making up 56.8 percent of cells, while the lymphocyte fractions showed clear age-related shifts: naive CD4 and CD8 T cells declined with age, whereas memory T cell fractions increased.

A central methodological hurdle the researchers had to overcome is collinearity. Blood cell fractions are not independent measurements; they are biologically correlated and mathematically constrained to sum to 100 percent. As the authors demonstrate with a series of example regressions, this makes effect sizes for individual cell types deeply ambiguous. When the neutrophil fraction was modeled alone, its apparent effect on age was nearly zero, but adjusting for memory CD4 T cells flipped the estimate positive, and adjusting for naive CD8 T cells flipped it negative. In multivariable models, whichever cell fraction was omitted to satisfy the mathematical constraint had its effect absorbed into the intercept, systematically skewing the coefficients of the remaining fractions. The total variance explained stayed constant, but the interpretation of individual effects became meaningless.

To escape this trap, the team turned to principal component analysis. Because twelve cell fractions contain only eleven independent pieces of information, the researchers computed eleven principal components, each an uncorrelated linear combination of the original fractions. The leading components proved biologically interpretable: the first was almost perfectly correlated with the neutrophil fraction, while the second captured the balance between naive and memory T cells, one of the most striking signatures of immunosenescence. Crucially, because principal components are orthogonal to one another, the effect of each can be estimated independently and reliably, a property the authors verified by showing that removing a component left the remaining effect sizes unchanged.

Applying this framework, the researchers found that cell composition explains a remarkable share of the variation in DNA methylation age itself. Across the six clocks studied, including the first-generation Hannum, Horvath, and Zhang clocks and the second-generation PhenoAge, GrimAge, and DunedinPACE measures, cell counts accounted for 44 to 53 percent of the variance in predicted age, with the naive-to-memory T cell balance the dominant contributor. Calendar age itself was 43.5 percent explainable by cell composition. Yet when the team examined age acceleration, the residual difference between predicted and chronological age, the picture changed dramatically. Associations weakened sharply, explaining at most 21 percent of variance, and the specific cells involved shifted: for second-generation clocks, neutrophils took center stage while T cell contributions largely faded.

The divergence between DNA methylation age and age acceleration carries a profound implication. If age acceleration truly represented “biological age,” then a one-year advance in predicted age should reflect the same underlying biology as a one-year excess over chronological age. The data show this is not the case, at least with respect to blood cell composition. The CpG sites making up first-generation clocks responded almost identically to calendar age and to age acceleration, with correlations between the two effect estimates reaching 0.80 to 0.91. For second-generation clocks, those correlations collapsed to between 0.13 and 0.50, and the age-acceleration estimates carried standard errors nearly three times larger, indicating substantial noise layered on top of genuinely distinct biology.

To establish that cell composition actually drives clock readings rather than merely correlating with them, the researchers performed an elegant validation experiment. They downloaded DNA methylation profiles of 56 purified blood cell samples from a public repository and constructed artificial cell mixtures in silico, blending the average methylation profile of each cell type in proportions matching the population mean. They then generated twelve additional mixtures, each time raising one cell fraction by one standard deviation while proportionally shrinking the others. Running the clocks on these synthetic samples reproduced the observational findings: boosting naive CD4 or CD8 T cells lowered predicted age acceleration for the Hannum, PhenoAge, GrimAge, and DunedinPACE clocks, while increasing neutrophils raised it. The Horvath and Zhang clocks remained largely indifferent to these manipulations.

The final question was whether this cell-composition signal contaminates the clinically important associations between epigenetic age acceleration and disease. Using data from 18,859 participants in the Generation Scotland cohort, the team tested the clocks against 176 incident health outcomes, including all-cause mortality. Cell composition itself was significantly associated with twelve outcomes after Bonferroni correction, among them mortality, asthma, and non-Hodgkin lymphoma, with mortality linked to neutrophil-related and regulatory T cell components but notably not to the naive-to-memory T cell ratio. When the researchers adjusted the clock-outcome associations for cell composition, the hazard ratios were attenuated for four of the six clocks, but only modestly, by roughly 2 to 7 percent overall and between 1 and 6 percent for mortality.

That modest attenuation is perhaps the study’s most reassuring finding for the field. Even though blood cell composition drives a substantial fraction of clock variation, it explains less than 10 percent of the association between age acceleration and incident disease. The authors suggest that neutrophil abundance, which does not change with chronological age yet tracks mortality, frailty, and inflammation, may act as a health-relevant biomarker that clocks capture independently of the aging process itself. This raises a deeper conceptual question: if changes in cell composition are part of how aging manifests in blood, for example through chronic inflammation, then adjusting them away in epigenetic association studies may discard biologically meaningful signal rather than confounding.

For the growing consumer market in epigenetic age testing, the message is one of caution and nuance. A high epigenetic age acceleration reading on a second-generation clock may partly reflect an elevated neutrophil fraction rather than accelerated cellular aging, while a Horvath or Zhang reading may be largely insensitive to immune composition but noisier as a health predictor. The researchers provide their principal component loadings and analysis code publicly, allowing other teams to project the same decomposition onto new datasets. As epigenetic clocks continue to migrate from research laboratories into clinics and commercial services, this work makes clear that interpreting what a clock is actually measuring requires looking carefully at the blood it was drawn from, and that the biology of predicted age and the biology of age acceleration are, in important respects, two different stories.

Subject of Research: The contribution of blood cell composition to DNA methylation age and epigenetic age acceleration

Article Title: Blood cell composition reveals distinct biological interpretation of DNA methylation age and age acceleration

Article References: Jonkman, T. H., Richmond, A., BIOS Consortium, Marioni, R. E., van Zwet, E. W., & Heijmans, B. T. (2026). Blood cell composition reveals distinct biological interpretation of DNA methylation age and age acceleration. Genome Medicine, 18(1), Article 142. https://doi.org/10.1186/s13073-026-01751-6

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01751-6

Keywords: epigenetic clocks, DNA methylation age, age acceleration, biological age, blood cell composition, T cells, neutrophils, immunosenescence, principal component analysis, collinearity, Genome Medicine, aging biomarkers

The biological target of the score is the senescence-associated secretory phenotype, or SASP, a cocktail of cytokines, chemokines, growth factors, proteases, and other molecules shed by senescent cells. Cellular senescence is a state of permanent cell-cycle arrest that is generally protective against cancer in the short term but becomes increasingly problematic with age. Senescent cells do not simply sit quietly; they remain metabolically active and progressively remodel their secretome, flooding surrounding tissue with inflammatory and tissue-remodeling signals. Through this secretory output, a relatively small population of arrested cells can exert outsized effects on neighboring and even distant tissues, promoting chronic inflammation, tissue dysfunction, and the multicolored tapestry of age-related disease, from heart failure to dementia. Because these molecules circulate in the blood, they offer an accessible window onto a burden that would otherwise require tissue biopsies to assess.

To build the score, the research team first curated a panel of 38 plasma proteins that are consistently dysregulated when cells of different types are pushed into senescence by different triggers. The list was assembled by cross-referencing databases such as CellAge, the SenNet Consortium’s markers, and the SASP Atlas, together with manual curation of the literature, and it includes well-known inflammatory messengers such as interleukin-6, CXCL8, CCL2, GDF15, and soluble tumor necrosis factor receptors. The team then turned to the UK Biobank Pharma Proteomics Project, which measured 2,923 plasma proteins in more than 54,000 participants using the Olink Explore 3072 proximity extension assay. After excluding three proteins with excessive missingness and imputing the remainder, the researchers worked with proteomic data from 50,997 participants, splitting them into a training set of 43,358 individuals and a held-out test set of 7,639.

The model at the heart of the SASP Score is a Guided AutoEncoder with Transformer, or GAET. Classic autoencoders compress high-dimensional input into a low-dimensional latent representation and then reconstruct the original data, a strategy that excels at nonlinear dimensionality reduction but can drift toward biologically meaningless encodings. The GAET adds an auxiliary guidance head that predicts chronological age from the latent representation during training, steering the model toward aging-relevant protein structure. Crucially, chronological age is used only as a training signal; once the model is trained or fine-tuned, the score itself is computed purely from protein measurements. The Transformer backbone, borrowed from the architecture that powers modern language models, encodes both the quantitative protein values and the textual identity of each protein through a dual-embedding mechanism, allowing the network to learn inter-protein dependencies while retaining the semantic anchors needed to transfer the model to other cohorts and assays.

The results in the UK Biobank test sample were striking. The SASP Score correlated strongly with chronological age (Spearman rho = 0.70) and with established composite measures of biological aging, including PhenoAge (rho = 0.66), BioAge (rho = 0.71), the proteomic aging clock (rho = 0.67), and the healthspan proteomic score (rho = −0.63). It also tracked weaker but consistent signals across physical and cognitive traits: higher scores went hand in hand with higher waist-to-hip ratio, higher body mass index, elevated systolic blood pressure, greater frailty on a 49-item index, shorter leukocyte telomeres, weaker grip strength, slower walking pace, and slower reaction times. Median scores were significantly higher in men, in adults aged 60 and over, in people with high waist-to-hip ratios, in former or current smokers, and in those with frailty, hypertension, or hypercholesterolemia.

Most consequentially, the score predicted what happened next. Over a mean follow-up of 13.3 years, each one-standard-deviation increase in the SASP Score was associated with a 41 percent higher risk of death (adjusted hazard ratio 1.41, 95 percent confidence interval 1.25 to 1.60), after accounting for age, sex, ethnicity, education, material deprivation, smoking, alcohol status, systolic blood pressure, and body mass index. The score was also significantly associated with the incidence of multiple age-related conditions, with particularly robust signals for chronic kidney disease, heart failure, lung cancer, and neurological disorders including delirium, dementia, and Parkinson’s disease. When the researchers stratified participants using a cutoff set at the 90th percentile of scores among healthy individuals, those above the threshold showed visibly worse Kaplan–Meier survival curves for mortality and several major chronic diseases.

Shapley Additive exPlanations analysis, a technique borrowed from machine-learning interpretability research, revealed which proteins carried the most weight in the score. The top five contributors were GDF-15, CXCL-9, PGF, TNFRSF11B, and CCL-20, a lineup that the authors interpret as highlighting mitochondrial function, immune signaling, and apoptosis control as central threads of the senescence secretome. Importantly, the composite score consistently outperformed any single protein in predicting mortality and nearly every age-related disease examined, with diabetes the lone exception. The researchers attribute this advantage to the model’s capacity to capture nonlinear interactions among proteins, which they argue better reflects the genuine complexity of the secretome than the one-marker-at-a-time approach used in most prior studies, an approach that also inflates the risk of spurious statistical associations through repeated testing.

The external validation came from the MEDEX study, a randomized clinical trial of 585 adults aged 65 to 84 that compared mindfulness-based stress reduction, multimodal exercise, and their combination in older people with subjective cognitive complaints. The team fine-tuned the pre-trained GAET model on MEDEX proteomic data, which had been generated on a completely different platform, a Luminex multiplex immunoassay, using conservative settings to avoid overfitting. In this healthier and age-restricted sample, the score correlated modestly with age (rho = 0.34) and comorbidity burden (rho = 0.16). The longitudinal results were arguably the most provocative finding of the study: over 18 months, the SASP Score rose significantly in participants who did not exercise, but showed no significant increase in those assigned to the exercise arm. Exercise did not lower the score, but it appeared to halt its age-related climb, a pattern the authors describe as consistent with a senomorphic, senescence-stabilizing effect of physical activity.

The authors are careful to position the SASP Score as a measure of one specific hallmark of aging rather than a general biological age clock, and they note that it can be used alongside proteomic aging clocks and organ-specific scores to give complementary views of an individual’s aging biology. They also acknowledge limitations: there is no consensus on a universal set of SASP markers, plasma protein levels may carry nonspecific inflammatory or tissue-damage signals, and the precise cellular sources of the circulating proteins remain unknown. Disease classification in the UK Biobank also lacks granularity for factors such as tumor subtype and stage. Even so, the ability to compute a senescence biomarker across different proteomic platforms, and to detect its stabilization in response to a non-pharmacological intervention, positions the score as a practical tool for observational studies and, perhaps more importantly, for clinical trials of senolytic and senomorphic drugs, where a sensitive, transferable readout of cellular senescence burden has been a long-standing unmet need.

Subject of Research: A deep learning–based composite blood biomarker of cellular senescence burden for predicting mortality and age-related health outcomes

Article Title: A Deep‐Learning Based Biomarker of Systemic Cellular Senescence Burden to Predict Mortality and Health Outcomes

Article References: Zhao, S., Kuo, C.-L., Lenze, E. J., Wetherell, J. L., Haynes, L., El‐Ahmad, P., Fortinsky, R., Kuchel, G., Harris, T., & Diniz, B. S. (2026). A Deep‐Learning Based Biomarker of Systemic Cellular Senescence Burden to Predict Mortality and Health Outcomes. Aging Cell, 25(10), Article e70737. https://doi.org/10.1111/acel.70737

Image Credits: AI Generated

DOI: 10.1111/acel.70737

Keywords: cellular senescence, SASP, deep learning, biomarker, UK Biobank, proteomics, aging, mortality, exercise, Transformer, autoencoder, geroscience

The central problem the forum addressed is one that has long frustrated the longevity field: aging is a complex, multifactorial process, and without reliable molecular measures of biological age it is extraordinarily difficult to demonstrate that any candidate intervention actually slows it. Chronological age is a poor proxy, because individuals of the same age can differ dramatically in health status, disease risk and physiological reserve. Biomarkers of aging, measurable indicators that track biological aging more faithfully than the passage of time, therefore serve as the linchpin for translating laboratory discoveries into clinical trials. The forum’s organizers argued that the field has reached a point where such frameworks must be standardized, validated and deployed in human studies rather than remaining confined to retrospective cohort analyses.

Among the most prominent themes was the continued evolution of epigenetic clocks, the DNA methylation-based estimators of biological age pioneered by Steve Horvath of the University of California, Los Angeles, who presented at the meeting. Horvath and collaborators recently described pan-mammalian clock models in Nature Communications in 2024, extending methylation-based age estimation across species and tissues. These models exploit the fact that cytosine methylation patterns at specific genomic sites change predictably with age, allowing regression-based models trained on large reference datasets to predict chronological age from a tissue sample. Deviations between predicted and chronological age, the so-called age acceleration, have been associated in numerous studies with mortality risk and age-related disease. The forum discussions reportedly focused on refining these tools, including second-generation clocks trained on mortality and morbidity outcomes rather than chronological age alone, and on the interpretive caveats that arise when clocks are used to evaluate interventions.

That caveat is a serious one, and it featured prominently in the technical discussions. Work published in Cell Metabolism in 2023 by Poganik and colleagues demonstrated that biological age, as read out by multiple independent biomarkers, is not a fixed quantity but can fluctuate in response to stress, surgery and severe illness, and can recover afterward. This transient age acceleration and subsequent restoration implies that a single snapshot of a biomarker may mislead trial designers, and that repeated longitudinal sampling is essential to distinguish durable rejuvenation from short-term perturbation. Forum participants emphasized that intervention trials must therefore incorporate repeated measurements, appropriate control groups and pre-registered analytical pipelines to avoid spurious conclusions about whether a treatment has genuinely slowed aging.

A second major strand concerned organ-specific and proteomic aging clocks. Rather than estimating the age of the whole organism, these models estimate the biological age of individual organs or physiological systems, revealing that organs within a single person can age at markedly different rates. Recent work published in Cell Metabolism in 2025 by Goeminne and colleagues, and other proteomic studies discussed at the forum, showed that plasma protein signatures can be decomposed into organ-derived aging signals, opening the possibility of identifying which organ is failing fastest in a given individual and tailoring interventions accordingly. Related work by Yu and colleagues in Cell Metabolism in 2024 and by Bi and colleagues in 2025 extended this organ-centric view, and presentations by researchers including Jing-Dong J. Han of Peking University and Guangju Ji of the Henan Academy of Sciences covered multi-omic and computational approaches to constructing and validating such signatures in large human cohorts.

Inflammation emerged as a recurring mechanistic thread connecting many of the biomarkers under discussion. David Furman of Stanford University and the Buck Institute for Research on Aging presented work on immune-system aging, including the inflammatory signature known as iAge, described in Nature Aging in 2021, which uses a small set of circulating immune and chemokine markers to predict age-related decline and multimorbidity. Because chronic low-grade inflammation, sometimes termed inflammaging, contributes to a broad range of age-associated pathologies, immune-focused biomarkers offer a mechanistically interpretable complement to epigenetic and proteomic clocks. Furman’s discussion of iAge also illustrated the translational pathway the forum sought to highlight, since the signature has been developed into a commercial platform intended to support clinical decision-making and intervention monitoring.

Cellular senescence, the state of irreversible growth arrest that accumulates in aged tissues and secretes inflammatory and matrix-degrading factors, formed another pillar of the program. Presentations by Ning Jiang of West China Hospital and other speakers addressed the identification and quantification of senescent cell burden in accessible tissues and biofluids, a prerequisite for testing senolytic drugs, the compounds designed to selectively eliminate senescent cells. The field’s challenge, as framed at the forum, is that senescence markers such as p16INK4a, senescence-associated beta-galactosidase and the senescence-associated secretory phenotype are heterogeneous and context-dependent, so a validated circulating biomarker panel for senescent cell load remains an urgent unmet need for the senolytics pipeline.

The forum also looked beyond humans to comparative biology as a source of intervention targets. Vera Gorbunova and Andrei Seluanov of the University of Rochester presented their work on long-lived and cancer-resistant rodents, including naked mole-rats and blind mole-rats, whose unusual genome maintenance and tumor-suppression mechanisms were detailed in a 2025 Nature paper by Firsanov and colleagues. Comparative studies of this kind identify naturally evolved protective mechanisms, such as enhanced DNA repair, high-molecular-mass hyaluronan and distinctive interferon responses, that can in principle be mimicked pharmacologically. Complementing this, Vincenzo Sorrentino of the National University of Singapore and Lu Dong discussed mitochondrial and proteostatic determinants of tissue aging, including work on NAD metabolism and the nutraceutical trigonelline published in Nature Metabolism in 2024, which linked circulating trigonelline levels to muscle mitochondrial function and suggested a plausible route to combating sarcopenia.

Genome instability and the limits of rejuvenation were addressed by Jan Vijg of Albert Einstein College of Medicine, whose presentations considered somatic mutation accumulation as a fundamental driver of aging and the implications this holds for how much biological age reversal is realistically achievable. Ana Maria Cuervo of Albert Einstein College of Medicine discussed chaperone-mediated autophagy, the selective lysosomal degradation pathway that declines with age, and the therapeutic prospects of pharmacologically restoring it. Raul Mostoslavsky of Massachusetts General Hospital and Harvard Medical School covered chromatin and metabolic regulation of aging, while Susanna Rosi of Altos Labs presented work on cellular reprogramming and neural rejuvenation, an approach that resets epigenetic age in specific cell populations and has shown functional recovery in models of brain injury and neurodegeneration.

The report closes by looking forward: the organizers announced a 7th TimePie Longevity Forum for 2026, and the emerging directions summarized in the meeting report point toward standardized, multi-modal biomarker panels that combine epigenetic, proteomic, immune and imaging readouts, deployed in longitudinal human cohorts and intervention trials. The competing-interest disclosures accompanying the report, which include inventorship on epigenetic biomarker patents, company founder roles and advisory positions among several authors, underscore how quickly the field is moving from academic measurement toward commercial application. What the Shanghai meeting made clear is that the bottleneck in geroscience is no longer the identification of candidate targets in model organisms but the credible demonstration, in people, that a therapy has changed the trajectory of biological aging, and that this demonstration will stand or fall on the quality of the biomarkers used to measure it.

Subject of Research: Aging biomarker development and geroscience intervention discovery discussed at the 6th TimePie Longevity Forum in Shanghai

Article Title: Advancing aging biomarkers and intervention discovery at the TimePie Longevity Forum

Article References: Ying, K., Bie, J., Chen, G., Cuervo, A. M., Deng, H., Dong, L., Furman, D., Gorbunova, V., Han, J.-D. J., Horvath, S., Ji, G., Jiang, N., Mostoslavsky, R., Rosi, S., Seluanov, A., Sorrentino, V., Tang, Y., Vijg, J., & Yang, Q. (2026). Advancing aging biomarkers and intervention discovery at the TimePie Longevity Forum. Nature Aging. https://doi.org/10.1038/s43587-026-01226-8

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01226-8

Keywords: aging biomarkers, epigenetic clocks, geroscience, longevity forum, cellular senescence, proteomic aging clocks, inflammaging, senolytics, chaperone-mediated autophagy, somatic mutations, comparative biology, NAD metabolism

The study, led by Kaitlin Casaletto, PhD, an associate professor at the UCSF Fein Memory and Aging Center, and co-senior author Rowan Saloner, PhD, also of the Fein Memory and Aging Center, focused on molecules circulating in the blood that are known to be linked to brain aging. Using a commercially available research blood test that measures more than a hundred such molecules, the team identified 16 whose levels changed in a coordinated way as women moved through menopause. Crucially, these molecular shifts tracked more closely with changing hormone levels than with chronological age, indicating that it was the hormonal upheaval of menopause itself — not simply the passage of time — that was driving the changes.

The implications are striking because two-thirds of people with Alzheimer’s disease are women, a disparity that cannot be explained by women’s longer average lifespans alone. Despite decades of research, scientists have struggled to pinpoint exactly what it is about women’s biology that makes them more vulnerable to dementia. The new findings point toward a compelling answer: the earliest brain changes associated with Alzheimer’s disease begin decades before symptoms appear, and for women, the biology of menopause may help set the stage for that process in midlife.

To capture the transition with unusual precision, the researchers recruited 80 women in their 40s and 50s and used a staging tool called STRAW+10, which combines reported symptoms with hormone measurements to determine exactly where each woman stood in the menopause transition. First author Madeline Wood Alexander, a graduate student at the University of Toronto, emphasized why this mattered. Many studies simply ask women whether they have gone through menopause and when, she noted, but her team wanted to capture the years of hormonal flux that unfold before and after the final menstrual period. Menopause is not a single moment; symptoms and hormone changes can begin as early as a decade before the last cycle and persist for years afterward, typically with the final period occurring around age 51.

What the team found was a coherent molecular fingerprint of the transition. Molecules associated with inflammation tended to rise as estradiol, the primary estrogen, declined. A separate group of molecules tied to Alzheimer’s disease biology rose in step with follicle-stimulating hormone, or FSH, which surges as the ovaries wind down. The pattern was not confined to the small UCSF cohort: when the researchers analyzed previously collected data from more than 2,800 women in the UK Biobank, they replicated the same molecular shifts, strengthening the case that this fingerprint is a general feature of the menopause transition rather than an artifact of one group of participants.

The most consequential discovery came when the scientists looked at the same molecules in older women. Drawing on data from nearly 12,000 women in their 60s and early 70s across four previous studies, they found that those with the highest levels of the menopause-linked molecules performed worse on memory and thinking tests and faced a 15 percent higher risk of developing Alzheimer’s disease as they aged. In other words, the molecular signature written during the hormonal turbulence of midlife appeared to remain legible in the blood decades later, and it correlated with real differences in cognition and disease risk. Saloner described the significance plainly: the team is identifying molecular shifts in blood in midlife postmenopausal women that also predict cognition later in life, making these molecules important markers of both menopause and cognitive aging.

One of the most intriguing findings involved vasomotor symptoms. Women who reported night sweats tended to show greater increases in inflammatory molecules during the transition, and that link proved remarkably durable. Older women who recalled having hot flashes during menopause still carried higher levels of those inflammatory markers years afterward. This suggests that the intensity of a woman’s menopausal symptoms may carry information about her underlying biology — not just her comfort in the moment, but potentially her long-term brain health trajectory. It is a finding that reframes symptoms often dismissed as a natural nuisance into potential clinical signals worth measuring.

The researchers are careful about what the study does and does not show. The findings are correlational, and the team does not yet know what brain changes or dementia risk factors the menopause transition may directly trigger. Casaletto stressed that the scientists do not think menopause is directly causing dementia. Rather, she explained, it may become possible to predict a woman’s risk for dementia decades later by measuring the levels of these molecules around the time of menopause. There is also a complicating observation: in a small sample of midlife men, much of the molecular fingerprint looked the same as it did in postmenopausal women. That hints that menopause may trigger a rapid shift in biological aging that unfolds far more gradually in men, raising new questions about how sex-specific reproductive biology and general aging processes intersect.

The long-term ambition is a familiar one drawn from cardiology: a routine blood test that works for dementia risk the way cholesterol panels work for heart disease. Such a test could identify women in midlife who might benefit from early interventions — whether lifestyle changes, monitoring, or eventually targeted therapies — long before any cognitive symptoms emerge. Casaletto argues that midlife is a critical window for both men and women, a period in which the brain can be set up to be more resilient or more vulnerable to dementia in later life. For women, she said, menopause may be an especially powerful time to intervene. Wood Alexander added an important framing note: menopause is a normal physiological process that everyone with ovaries who lives long enough will experience, and it should be viewed not as something bad but as an opportunity to understand and perhaps modify the biology of brain aging in women.

The science is now moving from cross-sectional snapshots to longitudinal observation. Casaletto, in collaboration with scientists around the country, is launching the Longitudinal Menopause Project, which will enroll its first participants and follow women through the entire menopause transition with twice-yearly blood draws, brain MRI scans, cognitive testing, wearable devices, and smartphone-based monitoring. Separately, Wood Alexander is recruiting women at the University of Toronto to measure molecular changes throughout menopause. Together, these efforts aim to confirm whether the 16-molecule fingerprint truly predicts individual outcomes, to disentangle which hormonal changes drive which molecular shifts, and to determine whether interventions during the transition can alter the trajectory. If they succeed, the years around a woman’s final menstrual period — long treated as an awkward gap in medical research — could become one of the most valuable early-warning checkpoints in the prevention of Alzheimer’s disease.

Subject of Research: Blood molecular changes during the menopause transition and their association with later-life cognitive decline and Alzheimer's disease risk

Article Title: Menopause leaves a fingerprint that may predict dementia risk

Article References: Menopause leaves a fingerprint that may predict dementia risk. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, Alzheimer's disease, dementia risk, blood biomarkers, estradiol, follicle-stimulating hormone, brain aging, inflammation, cognitive decline, UK Biobank, women's health, UCSF

The research, led by Mirko Di Rosa and Luca Soraci of IRCCS INRCA in Cosenza, Italy, together with colleagues at the University of Calabria and partner institutions, pooled individual-level data from four prospective European cohorts of older adults. The cohorts were deliberately heterogeneous: 812 community-dwelling older people from the ECHA-PC-MUSA studies, 813 nursing home residents from the SADEL cohort, 579 long-lived individuals and area-matched controls from the Genetics of Healthy Ageing project, and 4,400 hospitalized patients from the REPORTAGE project. In total, 6,604 people were followed for up to five years, and the mean age of the pooled sample was 84.8 years, with a standard deviation of 9.2 years. That breadth of settings is precisely what makes the analysis unusual; most previous studies of RDW and mortality have examined a single clinical population, leaving open the question of whether the marker truly travels across the diverse worlds of home, hospital, and long-term care.

Technically, RDW is reported as a coefficient of variation, the standard deviation of red cell volume divided by the mean corpuscular volume, multiplied by one hundred. It is generated automatically by automated haematology analysers at no additional cost, which is part of its appeal as a potential screening tool. In this study the primary exposure was an RDW-CV of 15 percent or higher, a threshold commonly used to flag anisocytosis, the technical term for increased variability in red cell size. Among the European participants, 41.4 percent met this criterion, and over the five-year follow-up period 69.9 percent of the cohort died, a striking figure that reflects the advanced age and clinical vulnerability of the populations studied.

To test whether elevated RDW was an independent predictor of death rather than a bystander marker of known risk factors, the investigators used multilevel Cox proportional hazards regression, treating the cohort of origin as a random effect. The models adjusted for a formidable battery of geriatric prognostic factors: age, sex, the presence of anaemia, serum albumin, the neutrophil-to-lymphocyte ratio as an index of systemic inflammation, the number of chronic diseases and medications, and impairment in activities of daily living. The models also pre-specified stratification at age 85, allowing the association to be examined separately in the oldest-old, a group in which mortality prediction is notoriously difficult because standard risk factors often lose discriminatory power.

The headline result was unambiguous. Older adults with RDW-CV at or above 15 percent had a 58 percent higher hazard of death during follow-up than those below the threshold, with a pooled adjusted hazard ratio of 1.58 and a 95 percent confidence interval running from 1.48 to 1.68, a finding highly statistically significant at p less than 0.001. Just as important as the magnitude was the consistency: between-cohort heterogeneity, quantified by the theta statistic, was minimal at 0.06, and the direction of the association was concordant in three of the four cohorts. In epidemiological terms, this suggests that the relationship is not an artefact of any single population or care setting but a robust phenomenon that persists whether the blood was drawn in a nursing home, a hospital ward, or a community clinic.

Replication is where many biomarker studies falter, so the team took the additional step of validating their findings externally in an entirely different healthcare system. They analysed 2,471 participants from the 2016 wave of the Health and Retirement Study, a large, nationally representative survey of older Americans. Once again, the elevated-RDW group showed significantly higher mortality, with a hazard ratio whose 95 percent confidence interval extended from 1.23 to 2.19 and a p value below 0.001. The fact that the association survived in a transatlantic sample, with different ancestry profiles, laboratory platforms, and care structures, strengthens the case that RDW captures something fundamental about biological risk rather than a local idiosyncrasy of Italian geriatric medicine.

Why should the variability of red blood cell size carry information about survival? The most widely discussed mechanism implicates chronic, low-grade systemic inflammation and its effects on erythropoiesis, the production of red cells in the bone marrow. Inflammatory cytokines disturb iron metabolism, shorten red cell lifespan, and disrupt the careful regulation of cell volume during maturation, producing a wider distribution of cell sizes. Elevated RDW has also been linked to oxidative stress, nutritional deficiencies, renal dysfunction, and subtle derangements of haematopoietic stem cell dynamics. In this sense, the authors argue, RDW may act as an integrative readout of physiological dysregulation, a single number that summarises the accumulated wear on multiple organ systems. Its independence from the neutrophil-to-lymphocyte ratio and albumin in the adjusted models suggests it is not simply proxying inflammation or malnutrition but adds a distinct dimension of prognostic information.

The association was strongest in the oldest-old, participants aged 85 and above, which is where the clinical implications become most interesting. Predicting mortality in very old patients is a persistent challenge for geriatric medicine; chronological age alone is a blunt instrument, and comprehensive geriatric assessment, while valuable, is time-consuming and requires trained personnel. A marker that costs nothing extra, is already reported on every blood count, and performs at a fixed cut-off across community, nursing home, and hospital populations could help clinicians stratify risk quickly at the bedside. It might, for example, inform decisions about the intensity of investigations, the appropriateness of aggressive interventions, or the prioritisation of patients for closer monitoring. The researchers are careful, however, to frame RDW as a prognostic indicator, not a deterministic verdict; a hazard ratio of 1.58 describes average risk at the population level, and individual outcomes will vary widely.

Several caveats temper the enthusiasm. This is an observational analysis, so elevated RDW identifies association rather than proven causation, and there is as yet no evidence that lowering RDW would change survival. The exposure was measured at a single time point, leaving open questions about the value of tracking RDW trajectories over time, and although the adjustment set was unusually comprehensive for a biomarker study, residual confounding can never be fully excluded. The predominance of Italian cohorts in the pooled European sample also invites replication in other national contexts, even given the American validation. Nonetheless, the study clears a high bar: a fixed, pre-specified threshold, individual-level pooling across markedly different care settings, adjustment for the major geriatric prognostic factors including anaemia, functional status, inflammation, and nutrition, minimal heterogeneity, and external replication in a second continent. Few routinely available laboratory measures can claim a comparable evidentiary pedigree.

The broader lesson may be about where medicine should look for its next generation of risk markers. As automated analysers quietly compute dozens of derived indices with every routine sample, some of the most informative signals may already be sitting in electronic health records, unexamined. Red cell distribution width, a number most patients have never heard of, now has credible evidence behind it as an independent predictor of five-year mortality in older adults across the full spectrum of care, from independent living to intensive hospital treatment. For a rapidly ageing global population, and for clinicians searching for cheap, scalable tools to guide geriatric care, a modest column of digits on a standard blood report may prove to be one of the most consequential numbers in the chart.

Subject of Research: Red cell distribution width as an independent predictor of five-year all-cause mortality in older adults across diverse care settings

Article Title: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation

Article References: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation. (n.d.). https://doi.org/10.1186/s12967-026-08997-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08997-z

Keywords: red cell distribution width, RDW, mortality, aging, geriatrics, complete blood count, oldest old, prognosis, cohort study, anaemia, inflammation, biomarker

The findings carry weight because of the peculiar biology of the fish involved. Annual killifishes inhabit ephemeral pools in Africa that dry out seasonally, and evolution has compressed their life cycles accordingly. Nothobranchius guentheri, commonly known as the redtail notho, reaches sexual maturity within weeks and typically lives only a year or so in captivity. This accelerated timetable makes it a powerful model for aging research, allowing scientists to observe in months the processes that unfold over decades in mice or humans. Despite decades of histological work on the species’ liver, kidney and immune organs, no broad biochemical survey of its aging process had previously existed, a gap the new study set out to close.

The experimental design was a cross-sectional one. Male and female fish were sampled at three ages, three, six and nine months, spanning juvenile adulthood through advanced old age for this species, yielding 20 analytical samples of whole-body homogenates. From each sample, the researchers quantified a standard panel of 27 clinical chemistry analytes, the same categories of markers a hospital laboratory measures in human patients: electrolytes such as sodium, potassium, calcium, magnesium and chloride; proteins including albumin and total protein; nitrogenous waste products such as creatinine; enzymes; glucose and fructose; cholesterol fractions; and markers of inflammation.

Age trends were assessed statistically in two complementary ways. Spearman rank correlation tested whether each analyte rose or fell monotonically with age, while two-way analysis of variance partitioned the effects of age, sex and their interaction. The results were dominated by downward slopes. Calcium showed the steepest and most statistically robust decline, with a correlation coefficient of minus 0.573 and a p-value of 0.008, followed by fructose at minus 0.507, albumin at minus 0.486 and magnesium at minus 0.479. Potassium narrowly missed the conventional threshold for significance at minus 0.422 with a p-value of 0.064. Only three markers, adenosine deaminase, C-reactive protein and HDL cholesterol, trended upward, and none of those trends reached statistical significance.

The steep drop in calcium and magnesium suggests a progressive breakdown of mineral homeostasis, a phenomenon long documented in aging humans, where declining bone formation and shifting electrolyte balance accompany frailty and increased mortality risk. The parallel fall in albumin is equally evocative. In humans, serum albumin concentration is one of the most reliable biochemical predictors of health in older people, low levels correlating with inflammation, malnutrition and shortened survival. Albumin also carries antioxidant properties, buffering oxidative damage throughout the circulation, so its age-related decline in the fish may reflect both shrinking synthetic capacity of the liver and a weakening of systemic antioxidant defenses.

Equally telling is what did not rise. In long-lived mammals, aging is typically accompanied by elevations in fasting glucose, circulating lipids and nitrogenous waste products such as urea and creatinine, changes that underpin the metabolic syndrome and chronic kidney decline. The killifish showed the opposite: a generalised downward drift across nearly the entire panel. The authors interpret this pattern most simply as the progressive loss of metabolically active tissue. As organs atrophy and cellular mass diminishes with age, the very substrates those tissues process, sugars, proteins and minerals, decline in parallel, rather than accumulating as waste. This makes the killifish profile qualitatively different from the human clinical picture and suggests that the fish’s terminal decline is driven by systemic attrition rather than by the chronic inflammatory and metabolic overshoot that characterizes mammalian gerontology.

Sex differences did emerge, however. Males carried higher levels of creatinine, carbon dioxide and HDL cholesterol than females, consistent with greater muscle mass and differing renal handling between the sexes. Sex-disparities in kidney disease and aging outcomes are well recognized in human epidemiology, and their appearance in a fish with such a radically different life history hints at deep evolutionary conservation of how male and female vertebrate bodies diverge in their metabolic architecture as they age.

Perhaps the most provocative element of the study is the hypothesis the authors attach to their data. Keepers of annual killifish have long observed an abrupt terminal mortality, fish that appear stable for months and then die suddenly. The new biochemical timeline offers a possible explanation: months of subclinical, invisible decline may proceed until physiological reserves, mineral balance, protein reserves and metabolic capacity, cross a critical threshold beyond which the animal can no longer maintain homeostasis and death follows quickly. The researchers frame this explicitly as a hypothesis for future testing rather than a proven mechanism, but it reframes the killifish’s apparent sudden death as the visible tip of a long biochemical slide.

The authors are candid about the limitations. Sample sizes were small, with 20 analytical samples spanning three ages and both sexes, and the p-values were uncorrected for multiple comparisons across the 27-analyte panel, so individual associations require confirmation in larger or longitudinal cohorts. Whole-body homogenates, while practical for fish of this size, blur tissue-specific signals that plasma measurements in larger animals would resolve. Nevertheless, the panel itself is a significant practical achievement: every marker can be read out within a single generation of the species, meaning the endpoints can serve rapid screening of lifespan-extending interventions such as dietary restriction or pharmacological compounds that have already shown promise in related killifish like Nothobranchius furzeri.

The study also slots into a much larger scientific narrative. Annual killifishes have become central players in geroscience, the interdisciplinary effort to link the biology of aging to chronic disease, and their genomes, evolution under extrinsic mortality and plasticity of lifespan under environmental manipulation have all been documented over the past two decades. What this new work adds is a bridge between molecular hallmarks of aging and whole-organism clinical chemistry, showing that even a vertebrate engineered by evolution for a compressed life undergoes a measurable, multi-system biochemical decline. For researchers hunting interventions that preserve physiological function rather than merely extend time, the humble redtail notho now offers a blood-test-style readout of aging itself, deliverable within months rather than decades, and a reminder that the body’s collapse with age may take different chemical routes in different lineages while obeying strikingly similar rules of gradual, systemic loss.

Subject of Research: Age-related biochemical profiling of the annual killifish Nothobranchius guentheri

Article Title: Age-related biochemical profiling reveals multi-system physiological decline in the annual fish Nothobranchius guentheri

Article References: Pawar, R., & Zhang, S. (2026). Age-related biochemical profiling reveals multi-system physiological decline in the annual fish Nothobranchius guentheri. Biogerontology, 27(5), Article 151. https://doi.org/10.1007/s10522-026-10493-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10493-2

Keywords: Nothobranchius guentheri, annual killifish, aging biomarkers, clinical chemistry, serum albumin, mineral homeostasis, whole-body homogenate, physiological decline, geroscience, Biogerontology, Age-related, biochemical